Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Propanc Biopharma Inc PPCB

Healthcare Biotechnology
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from... see more

Recent & Breaking News (OTCPK:PPCB)

Propanc Biopharma's Peer Reviewed Articles for Proenzymes Cancer Treatment Generates "Unprecedented" Interest

Business Wire August 21, 2024

Propanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North America

Business Wire August 14, 2024

Propanc Biopharma's CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors

Business Wire July 17, 2024

Propanc Biopharma Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office

Business Wire June 25, 2024

Propanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office

Business Wire April 16, 2024

Propanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

Business Wire April 8, 2024

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

Business Wire February 22, 2024

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

Business Wire January 16, 2024

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

Business Wire December 18, 2023

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

Business Wire November 7, 2023

Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia

Business Wire August 15, 2023

Propanc Biopharma's Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030

Business Wire July 25, 2023

Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads

Business Wire July 13, 2023

Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors

Business Wire July 5, 2023

Propanc Biopharma Provides Shareholder Update

Business Wire June 22, 2023

Propanc Biopharma Announces Strategic Pharma Partnering Initiative

Business Wire June 6, 2023

Propanc Biopharma's Intellectual Property Portfolio Makes Important Advancements in Europe

Business Wire May 25, 2023

Propanc Biopharma's Intellectual Property Portfolio Achieves Significant Milestones in North America

Business Wire May 23, 2023

Propanc Biopharma Announces Reverse Stock Split

Business Wire May 22, 2023

Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer

Business Wire March 28, 2023